CY2512B1 - Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application - Google Patents

Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Info

Publication number
CY2512B1
CY2512B1 CY0500026A CY0500026A CY2512B1 CY 2512 B1 CY2512 B1 CY 2512B1 CY 0500026 A CY0500026 A CY 0500026A CY 0500026 A CY0500026 A CY 0500026A CY 2512 B1 CY2512 B1 CY 2512B1
Authority
CY
Cyprus
Prior art keywords
valaciclovir
genital herpes
pharmaceutically acceptable
acceptable salt
suppression
Prior art date
Application number
CY0500026A
Other languages
English (en)
Inventor
John Delehanty
Margaret L Smiley
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24399659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2512(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY2512B1 publication Critical patent/CY2512B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0500026A 1996-01-19 2005-04-18 Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application CY2512B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59944896A 1996-01-19 1996-01-19

Publications (1)

Publication Number Publication Date
CY2512B1 true CY2512B1 (en) 2005-12-23

Family

ID=24399659

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500026A CY2512B1 (en) 1996-01-19 2005-04-18 Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Country Status (12)

Country Link
EP (1) EP0874631B1 (de)
JP (1) JP4097698B2 (de)
AT (1) ATE254463T1 (de)
AU (1) AU722304B2 (de)
CA (1) CA2243237C (de)
CY (1) CY2512B1 (de)
DE (1) DE69726255T2 (de)
DK (1) DK0874631T3 (de)
ES (1) ES2210490T3 (de)
PT (1) PT874631E (de)
WO (1) WO1997025989A1 (de)
ZA (1) ZA97400B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
ITMI20010009A1 (it) * 2001-01-03 2002-07-03 Menarini Ricerche Spa Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
IL160721A0 (en) * 2001-09-07 2004-08-31 Teva Pharma Crystalline forms of valacyclovir hydrochloride
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
JP4669804B2 (ja) * 2006-03-28 2011-04-13 株式会社オーディオテクニカ コンデンサマイクロホン
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
CN104188928B (zh) * 2014-09-17 2017-07-28 山东新时代药业有限公司 一种盐酸伐昔洛韦片剂及其制备方法
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN109651371B (zh) * 2018-12-31 2021-02-23 辰欣药业股份有限公司 一种盐酸伐昔洛韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CA2243237A1 (en) 1997-07-24
JP4097698B2 (ja) 2008-06-11
ATE254463T1 (de) 2003-12-15
EP0874631A1 (de) 1998-11-04
DK0874631T3 (da) 2004-03-22
ES2210490T3 (es) 2004-07-01
CA2243237C (en) 2008-09-02
AU722304B2 (en) 2000-07-27
EP0874631B1 (de) 2003-11-19
ZA97400B (en) 1997-11-13
PT874631E (pt) 2004-04-30
JP2000503310A (ja) 2000-03-21
AU1443497A (en) 1997-08-11
WO1997025989A1 (en) 1997-07-24
DE69726255T2 (de) 2004-08-26
DE69726255D1 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
CY2512B1 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
JP3924321B2 (ja) 疼痛軽減医薬組成物及び疼痛軽減方法
NZ508526A (en) Opioid formulations for treating pain
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
MY125662A (en) Pharmaceutical formulations containing darifenacin
RU2000111506A (ru) Таблетки с пролонгированным выделением для лечения болезни паркинсона
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JPH02502278A (ja) とくに後天性免疫不全状態の処置のための、免疫調整及び抗ウイルス効果を有する医薬の調製におけるモルヒネ拮抗剤の使用
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2795038C (en) Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
MY124465A (en) Reduction of infarct volume using citicoline
JPH08283148A (ja) うつ性症状改善剤
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
WO1992015315A1 (en) Method for the treatment of herpes
CN112972448B (zh) 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
HU211305A9 (en) Novel method for treatment of parkinson's disease
AR020167A1 (es) Metodo para la prevencion del inicio del asma
EP2892533A1 (de) A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion
JP4344532B2 (ja) 鼻炎用組成物
JP2004026810A (ja) 鼻炎用組成物
JPH06279282A (ja) 鎮痛製剤
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней